טוען...
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
Following the discovery that nearly half of all cutaneous melanomas harbour a mutation in the BRAF gene, molecular targeted kinase inhibitors have been developed for the treatment of metastatic melanoma and have dramatically improved outcomes for those patients with BRAF mutant disease, achieving hi...
שמור ב:
| הוצא לאור ב: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
SAGE Publications
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4346212/ https://ncbi.nlm.nih.gov/pubmed/25755684 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834014566428 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|